Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01426399
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Liraglutide and Heart Failure in Type 2 Diabetes
- Conditions
- Congestive Heart FailureType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Thomas Nystrom
- Target Recruit Count
- 62
- Registration Number
- NCT01425580
- Locations
- 🇸🇪
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden
🇸🇪Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB, Stockholm, Sweden
Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea
- Conditions
- Weight GainAmenorrhea
- Interventions
- Other: Starch tabletsDrug: Metformin
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Central South University
- Registration Number
- NCT01423487
- Locations
- 🇨🇳
Mental Health Institute of The Second Xiangya Hospital, Changsha, Hunan, China
Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess
- Conditions
- ObesityHyperandrogenemiaPolycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 20
- Registration Number
- NCT01422746
- Locations
- 🇺🇸
University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States
Adipokines in Obese Adolescents With Insulin Resistance
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Hospital Regional de Alta Especialidad del Bajio
- Target Recruit Count
- 31
- Registration Number
- NCT01410604
- Locations
- 🇲🇽
Hospital Regional de Alta Especialidad del Bajío, León, Guanajuato, Mexico
🇲🇽Hospital Infantil de México Federico Gómez, México, Distrito Federal, Mexico
Drug-Drug Interaction Study With Metformin and Nizatidine
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT01409395
- Locations
- 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States
Drug-drug Interaction Study With Metformin and Imatinib
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 11
- Registration Number
- NCT01404715
- Locations
- 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States
The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 37
- Registration Number
- NCT01400191
- Locations
- 🇩🇰
Clinical pharmacology, Institute og public health, University of Southern Denmark, Odense, Denmark
Pioglitazone and Metformin in Diabetic Children
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2011-07-19
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 56
- Registration Number
- NCT01396564
- Locations
- 🇲🇽
Endocrine Outpatient Clinic of the Hospital de Pediatria del CMN "Siglo XXI", Mexico City, DF, Mexico
Metformin & Inflammation in Pre-diabetic Children
- Conditions
- Glucose IntoleranceInflammationDiabetes
- Interventions
- Drug: MetforminDrug: placebo
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 52
- Registration Number
- NCT01394887
- Locations
- 🇲🇽
Endocrine Outpatient Clinic of the Hospital de Pediatria del CMN "Siglo XXI", Mexico City, DF, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.